From research to regulated: challenges in transferring methods
From research to regulated: challenges in transferring methods
The current decade has seen an evolution in biomarker research, with a breakthrough from traditional single analyte studies to simultaneous multiple analyte technologies, aided by the progressive development of research tools and the discovery of many novel biomarkers. It is foreseeable that the application of such technologies will have an integral role in clinical studies for establishing biomarker profiles of disease status and prognosis. However, the transfer of such complex procedures to a regulated environment presents many obstacles. Here, we discuss some of these applied technologies and the validation approaches we have taken as an academic unit to prove their suitability and appropriateness for clinical application. We discuss the advantages and limitations for such end point assays in early Phase clinical trials
285-291
Chowdhury, Ferdousi
0af499d4-17c5-40cf-9426-0d509ab82595
Williams, Anthony P.
973ff46f-46f1-4d7c-b27d-0f53221e4c44
May 2009
Chowdhury, Ferdousi
0af499d4-17c5-40cf-9426-0d509ab82595
Williams, Anthony P.
973ff46f-46f1-4d7c-b27d-0f53221e4c44
Chowdhury, Ferdousi and Williams, Anthony P.
(2009)
From research to regulated: challenges in transferring methods.
Bioanalysis, 1 (2), .
(doi:10.4155/bio.09.51).
Abstract
The current decade has seen an evolution in biomarker research, with a breakthrough from traditional single analyte studies to simultaneous multiple analyte technologies, aided by the progressive development of research tools and the discovery of many novel biomarkers. It is foreseeable that the application of such technologies will have an integral role in clinical studies for establishing biomarker profiles of disease status and prognosis. However, the transfer of such complex procedures to a regulated environment presents many obstacles. Here, we discuss some of these applied technologies and the validation approaches we have taken as an academic unit to prove their suitability and appropriateness for clinical application. We discuss the advantages and limitations for such end point assays in early Phase clinical trials
This record has no associated files available for download.
More information
Published date: May 2009
Identifiers
Local EPrints ID: 157333
URI: http://eprints.soton.ac.uk/id/eprint/157333
ISSN: 1757-6180
PURE UUID: 347f5cc6-58ec-47e8-9b0b-414e2fe95572
Catalogue record
Date deposited: 04 Jun 2010 14:14
Last modified: 14 Mar 2024 01:46
Export record
Altmetrics
Contributors
Author:
Ferdousi Chowdhury
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics